Friday, December 5, 2025

BTS’s ‘Spring Day’ Breaks 1 Billion Streams on Melon

BTS’s "Spring Day" is Melon’s first song to surpass 1 billion streams and has maintained a record seven-year chart presence.

Cho Tae Yul and Wang Yi Poised for Talks on U.S.-China Tariffs and North Korea at Munich Security Conference

South Korea's Foreign Minister Cho Tae Yul will meet China's Wang Yi at the Munich Security Conference amid rising US-China trade tensions.

Porsche’s First Electric SUV Now Available for Pre-Order

Porsche Korea announced that it will conduct pre-orders for its first electric SUV, the Macan Electric.

Health

The Easiest Way To Lose Investor Trust? Just Steal $6.7 Billion! BMS Masterclass In Bad Business

Bristol Myers Squibb faces a $6.7B lawsuit over alleged delays in drug approvals affecting former Celgene shareholders' payouts.

Global Pharma Giants Join Samsung Biologics in Major Climate Pledge to Cut Supply-Chain Emissions by 2030

Samsung Biologics leads a global initiative to reduce carbon emissions in healthcare, aiming for sustainability and renewable energy by 2030.

TRUST ME, I’m an Expert: Trump’s Tylenol-Autism Claim Exposes Washington’s Dangerous NEW Brand of Idiocy

Trump claims Tylenol during pregnancy may raise autism risk, but medical experts refute this as unsupported by scientific evidence.

GAME OVER: Samsung Biologics Declares War With ‘ExellenS’—A Standard That Kills All Biotech Competition

Samsung Biologics launches ExellenS in Europe, enhancing biopharmaceutical production with standardized quality and efficiency.

Chinese & Indian Medical Invasion: Pharmaceutic Dependency on Risk of Essential Medicine Supply

Concerns rise over South Korea's API industry reliance on China and India, with self-sufficiency at a record low of 25.6% in 2023.
Latest

Samsung Biologics Targets Japan’s $12.3 Billion CDMO Market: What You Need to Know

Samsung Biologics expands in Japan, targeting top pharma firms with new CMO brand 'ExellenS' and enhancing production capabilities.

Lotte Biologics Unveils Dual-Site Strategy: A Game Changer for Global CDMO in 2027

Lotte Biologics aims to lead in the evolving biotech landscape with dual sites in the U.S. and South Korea, enhancing global supply chains.

From R&D to Global Blockbuster: Fexuclue Sparks a New Vision for Daewoong

Daewoong Pharmaceutical's Fexuclue achieves rapid success with innovative marketing and aims for significant growth in treating GERD.

Fever’s Bigger Risk: Why the Tylenol Controversy Puts Moms in a Bind

Controversy surrounds acetaminophen use during pregnancy and its alleged link to autism, but evidence remains inconclusive.

Is Tylenol Dangerous for Pregnant Women? Trump’s Controversial Claims Debunked by Experts

UK Health Secretary counters Trump's claim linking Tylenol to autism, affirming its safety for pregnant women based on scientific studies.

Trump’s Next Target: Big Pharma’s Tylenol. Why He’s Questioning a $1B Industry

Trump links Tylenol to autism risk, announcing new FDA guidelines and studies, but scientific consensus remains unestablished.

Celltrion’s ‘Psoriasis’ Biosimilar Poised to Challenge Big Pharma with Phase 1 Data

The EADV conference in Paris showcased Celltrion's biosimilar CT-P55, confirming its equivalence to Cosentyx in safety and pharmacokinetics.

Bio-Revolution: Celltrion’s $700M Biosimilar Is Reshaping the Global Drug Market

Celltrion's breakthrough in antibody biosimilars is transforming healthcare, enhancing access and innovation in treatment options.

Sales and Trust: How Celltrion is Revolutionizing the European Market Directly Connected

Celltrion leverages direct sales in Europe to enhance trust and supply stability while introducing biosimilars like Omlyclo for asthma treatment.

Tylenol Stock Plunges: Trump’s Autism Warning Rattles $17B Market

Tylenol faces scrutiny over potential autism link during pregnancy, with mixed responses from the medical community and FDA caution.

Celltrion’s Biosimilar Success in Europe Paves the Way for a US Market Takeover

Celltrion's booth at EADV 2025 highlighted biosimilar innovations, showcasing promising clinical trial results and expanding treatment access.

Biosimilars No Longer Second-Best: Highlighting Cost Savings and Improved Patient Access

Biosimilars are becoming standard care, with growing confidence in their safety and efficacy, driven by cost savings and improved accessibility.

The Next Trillion-Dollar Bet: Korean Pharma Invests in Immuno-Oncology, Targeting a $1 Trillion Global Market

Cho Yong-joon outlines Dongkoo Bio's transformation into a global healthcare leader, emphasizing convergence and innovative growth strategies.

Saving Poverty vs Free Trade Society? How Celltrion’s Biosimilar Could Reshape the U.S. Healthcare Market

Professor Metz highlights biosimilars' potential to expand patient access to treatments, emphasizing Omliclo's impact at EADV conference.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.